February 15-20, San Fancisco: Translating Cancer Therapy from Promise to Reality

There is a great need for more effective and less toxic therapies for metastatic cancer patients. Advances in genetically engineered T cells is demonstrating clinical efficacy, eliminating many side effects from traditional chemo- and radiation therapies. Cambridge Healthtech Institute's Inaugural Clinical Cancer Immunotherapy symposium will demonstrate bench to bedside translation of combination immunotherapies, adoptive T cell therapies, as well as molecular targeted therapies. Case studies using prognostic biomarkers to predict immunotherapy response will also be showcased. The human immune system is inherently capable of recognizing and destroying cancer cells. At this event, attendees will learn more about the translational advances that are converting the promise of immunotherapy into reality for cancer treatment.